Devic?s Syndrome Treatment Market

Devic?s syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord.

Devic?s Syndrome Treatment Market contains market size and forecasts of Devic?s Syndrome (Neuromyelitis Optica) Treatment in Global, including the following market information:

Global Devic?s Syndrome (Neuromyelitis Optica) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Devic?s Syndrome (Neuromyelitis Optica) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Eculizumab Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Devic?s Syndrome (Neuromyelitis Optica) Treatment include Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Lupin Ltd., Sagent Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., Sandoz Inc. (Novartis) and Alkem Laboratories Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Devic?s Syndrome (Neuromyelitis Optica) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Devic?s Syndrome (Neuromyelitis Optica) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Devic?s Syndrome (Neuromyelitis Optica) Treatment Market Segment Percentages, by Type, 2021 (%)

Eculizumab

Methylprednisolone

Azathioprine

Mycophenolate Mofetil

Rituximab

Global Devic?s Syndrome (Neuromyelitis Optica) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Devic?s Syndrome (Neuromyelitis Optica) Treatment Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinic

Others

Global Devic?s Syndrome (Neuromyelitis Optica) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Devic?s Syndrome (Neuromyelitis Optica) Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Devic?s Syndrome (Neuromyelitis Optica) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Devic?s Syndrome (Neuromyelitis Optica) Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Alexion Pharmaceuticals, Inc.

Teva Pharmaceuticals

Fresenius Kabi AG

Pharmacia & Upjohn (a subsidary of Pfizer)

Lupin Ltd.

Sagent Pharmaceuticals, Inc.

Zydus Pharmaceuticals, Inc.

Sandoz Inc. (Novartis)

Alkem Laboratories Ltd.

Mylan Pharmaceuticals, Inc.

Hoffmann-La Roche/ Chugai Pharmaceutical

MedImmune LLC

RemeGen, Ltd.